id,agency_id,docket_id,title,document_type,subtype,posted_date,posted_year,posted_month,comment_start_date,comment_end_date,last_modified,fr_doc_num,open_for_comment,withdrawn,object_id
FDA-2025-P-7376-0008,FDA,FDA-2025-P-7376,Completeness Assessment Correspondence,Other,Assessment Document or Analysis,2026-02-10T05:00:00Z,2026,2,2026-02-10T05:00:00Z,,2026-02-11T00:17:09Z,,0,0,09000064b919f2bb
FDA-2025-P-7376-0007,FDA,FDA-2025-P-7376,"Amendment from WhiteOak Group, LLC",Other,Ammendment,2026-01-27T05:00:00Z,2026,1,,,2026-02-02T21:09:43Z,,0,0,09000064b91858a8
FDA-2025-P-7376-0001,FDA,FDA-2025-P-7376,"Suitability Petition from The WhiteOak Group, LLC (on behalf of Hybio Pharmaceutical Co., Ltd.)",Other,Petition(s),2025-12-29T05:00:00Z,2025,12,2025-12-29T05:00:00Z,,2025-12-30T01:32:13Z,,1,0,09000064b910b8b8
FDA-2025-P-7376-0006,FDA,FDA-2025-P-7376,Attachment 4,Supporting & Related Material,Background Material,2025-12-29T05:00:00Z,2025,12,,,2025-12-30T01:36:41Z,,0,0,09000064b910b481
FDA-2025-P-7376-0002,FDA,FDA-2025-P-7376,"Acknowledgement Letter from FDA DMB to The WhiteOak Group, LLC (on behalf of Hybio Pharmaceutical Co., Ltd.)",Other,Acknowledgement Letter/Receipt,2025-12-29T05:00:00Z,2025,12,2025-12-29T05:00:00Z,,2025-12-30T01:36:19Z,,0,0,09000064b910b8c1
FDA-2025-P-7376-0003,FDA,FDA-2025-P-7376,Attachment 1,Supporting & Related Material,Background Material,2025-12-29T05:00:00Z,2025,12,,,2025-12-30T01:36:34Z,,0,0,09000064b910b47a
FDA-2025-P-7376-0005,FDA,FDA-2025-P-7376,Attachment 3,Supporting & Related Material,Background Material,2025-12-29T05:00:00Z,2025,12,,,2025-12-30T01:36:39Z,,0,0,09000064b910b480
FDA-2025-P-7376-0004,FDA,FDA-2025-P-7376,Attachment 2,Supporting & Related Material,Background Material,2025-12-29T05:00:00Z,2025,12,,,2025-12-30T01:36:37Z,,0,0,09000064b910b47e